Aptevo Q2 2026: $13.1M Loss, Going Concern Warning, and $4.5M Financing
APVO is trading near its 52-week low of $3.35 (4.8% above the low).
Summary
Aptevo reported a $13.1M H1 2026 net loss, reiterated going concern doubts, and disclosed a $4.5M financing with heavy warrant overhang.
Key Events · Earnings and Guidance · APVO
-
Q2 2026 Net Loss of $13.1M
For the six months ended June 30, 2026, Aptevo reported a net loss of $13.1 million, compared to $12.6 million in the prior year period. Cash and cash equivalents fell to $9.8 million from $21.6 million at year-end 2025.
-
Going Concern Warning Reiterated
Management states that substantial doubt exists about the company's ability to continue as a going concern for the one-year period from the issuance date, citing recurring losses and negative cash flows. The company will need to raise additional funds.
-
$4.5M Financing with Heavy Warrant Overhang
On August 12, 2026, Aptevo entered into a private placement and warrant inducement transaction, issuing 861,708 shares and warrants to purchase up to 4,308,540 additional shares at $4.03 per share, for gross proceeds of $4.5 million. This creates significant potential dilution.
-
Nasdaq Delisting Risk
The company faces potential delisting from Nasdaq under the new Market Value Requirement of $5 million, which provides no cure period. As of August 12, 2026, the stock price was $3.50, and the market value of listed securities is near the threshold.
Analysis · APVO · Life Sciences
Aptevo's Q2 2026 10-Q reveals a $13.1 million net loss for the first half of 2026, with cash dwindling to $9.8 million. Management reiterates substantial doubt about the company's ability to continue as a going concern, citing the need for additional capital. The filing also discloses a $4.5 million private placement and warrant inducement completed on August 12, 2026, which introduces significant potential dilution. The stock trades near its 52-week low, and the company faces Nasdaq delisting risk under the new Market Value Requirement.
At the time of this filing, APVO was trading at $3.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.2M. The 52-week trading range was $3.35 to $48.78. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.